Bayer will cap R&D budget at $4.1B

With R&D expenses expected to surge 13 percent this year at Bayer, Germany's largest drug company, CEO Marijn Dekkers is telling reporters that he plans to make sure the budget item flatlines at $4.1 billion for 2011. Dekkers also noted that he was concerned "whether society will be prepared to pay an appropriate price for innovations in the future." Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.